Click here to read the latest cannabis quarterly update.

As the effects of the novel coronavirus continue to spread across countries and industries, the cannabis market is facing its own set of challenges.


Following a difficult first quarter, in Q2 cannabis names have seen continued impacts from the pandemic, which is affecting the entire global economy. However, there have also been positive signs thanks to the pantry-stocking activity seen among consumers.

As multi-state operators in the US captivate the market’s attention with their results, some of the industry’s largest players in Canada are beginning to experience consolidation as companies previously interested in expansion cut back and focus on essential output.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Overall, investors have faced ups and downs with cannabis in 2020, and the Investing News Network’s (INN) cannabis market update covers some of the most relevant elements from Q2.

Cannabis market update: COVID-19’s business impact

Prior to the COVID-19 outbreak, the Canadian cannabis sector was facing increasing pressure after failing to deliver on the lofty results expected before and after recreational legalization in Canada.

This year, the economic downturn attached to the virus has only added to the strain on the industry. One of the primary concerns for cannabis public names throughout North America has been the amount of investment capital available during the pandemic and moving beyond it.

Despite those concerns, there is optimism among some market watchers who believe valuations in cannabis are becoming more measured. Experts also agree that capital from institutional investors is ready to be deployed as soon as the US eases up on its cannabis regulations.

Similarly, on the cannabis stage outside North America — particularly in Australia — there’s been encouraging commentary about the availability of capital for cannabis operations.

Aside from its effects on capital, various analysts have highlighted the way COVID-19 lockdowns in Canada and the US have led to higher recreational product sales.

In a monthly commentary note, the managers of the Ninepoint Alternative Health Fund, which has exposure to a number of cannabis stocks, describe the pantry-stocking effect as an event seen “through the lockdown and post lockdown.”

The fund is managed by Charles Taerk, president and CEO of Faircourt Asset Management, and Douglas Waterson, CFO and portfolio manager with Faircourt.

The uptick in recreational product sales is important for Canadian cannabis producers as oversupply is an accepted ailment for the industry at large. And even with higher sales, this oversupply looks set to continue as inventories in the country reach new highs.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

“The lockdown has played into a strength for cannabis,” Taerk and Waterson wrote in their note to investors for the month of June.

Cannabis market update: All eyes on the US politics

When it comes to the cannabis stock universe, it’s become clear for industry observers that the growth opportunity has moved largely to the US market.

With an upcoming presidential election, investors are evaluating all the possibilities for how any kind of cannabis reform could fit into the bigger picture.

While it remains to be seen what kind of heft the cannabis legalization conversation will carry between US President Donald Trump and presumptive Democratic presidential nominee Joe Biden, some forms of cannabis reform are moving ahead in the political system.

For example, the much-anticipated SAFE Banking Act has now been attached to the HEROES Act, a new piece of Democratic-led policy. The SAFE Banking Act seeks to offer banking protections to cannabis businesses in legal states despite the federal illegality of the drug.

The new HEROES Act is primarily designed as a stimulus bill geared at balancing the effects of the coronavirus, and it made its way through the House of Representatives in May. However, it remains at the Republican-controlled Senate for the moment.

The managers of both the Ninepoint Alternative Health Fund and the Purpose Marijuana Opportunities Fund (NEO:MJJ) have highlighted how significant it would be for US banking limitations to be lifted.

During the Q2 period, the managers of the Ninepoint Alternative Health Fund consistently praised the performance of Trulieve Cannabis (CSE:TRUL,OTCQX:TCNNF) and Green Thumb Industries (CSE:GTII,OTCQX:GTBIF).

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

In a note to investors, the fund managers at Purpose Investments highlighted the following states as areas of growth for patient numbers related to cannabis figures:

  • Florida
  • Ohio
  • Pennsylvania
  • New Jersey
  • New York

Cannabis market update: Future M&A projections

The high number of cannabis stocks has been a topic of note for awhile now, and discussion around cannabis company sizes has been growing as well.

Investors are starting to see the effects of mergers and acquisitions (M&A) as a consolidation tactic, as well as the troubling acceleration of bankruptcies and struggling roadmaps for some of the less-prepared names in the cannabis market thanks to financial pressures from the coronavirus.

“As the industry matures over the near term, much more M&A is expected,” Jefferies analyst Owen Bennett wrote in a note to clients issued in June.

The biggest Canadian companies — including, but not limited to, Canopy Growth (NYSE:CGC,TSX:WEED), Aphria (NASDAQ:APHA,TSX:APHA), Aurora Cannabis (NYSE:ACB,TSX:ACB), HEXO (NYSE:HEXO,TSX:HEXO), Tilray (NASDAQ:TLRY) and Sundial Growers (NASDAQ:SNDL) — have all cut back on staff and operations to save on costs.

However, one expert thinks consolidation for Canadians firms is becoming more and more about actual company operations and less about the whole sector shrinking by way of M&A activity.

“I think most consolidation has come in the way of minimizing footprints for a lot of these companies, rather than just the straight out bankruptcy, and I think it comes from that entrepreneurial spirit that’s still very much embedded within the management teams on some of these companies that know that they’re only a stone’s throw away from profitability,” Nawan Butt, portfolio manager with Purpose Investments, told INN.

Butt, alongside Greg Taylor, chief investment officer at Purpose Investments, serves as the fund manager for the publicly traded Purpose Marijuana Opportunities Fund.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

In their May commentary note to investors, the Purpose Investments experts opined that the downsizing and layoffs seen among Canadian cannabis companies will ultimately help the industry get to a more appropriate size and valuation.

“A significant consolidation is currently underway in Canada with a handful of bankruptcies already accounted for and many licensed producers (LPs) running on fumes,” Butt and Taylor said in their commentary note for the month of July.

Butt told INN he sees the consolidation trend evolving beyond companies acquiring each other or joining forces in order to survive.

“In previous months, LPs have used COVID-19 as an excuse to downsize production and implement ‘temporary’ layoffs,” he said. “We, however, view this as a rightsizing for the industry and ultimately a net positive as production moves down towards actual industry demand.”

He envisions consolidation dominating the conversation into the second half of 2020 and beyond.

“Those that should have consolidated, those that should have been shut down by now, have been given this last lifeline by the industry, a last little bit of money to keep on going to see if they can prove themselves,” he told INN. This time extension Butt refered to is approximately six to 12 months.

Cannabis market update: Investor takeaway

Cannabis investments have morphed from an exciting up-and-coming proposition into a more grown-up industry trying to re-establish its footing and adjust to the scrutiny of investors.

During his talk at the Prohibition Partners LIVE online event, Alan Brochstein, analyst and industry commentator with 420 Investor and New Cannabis Ventures, confirmed that the cannabis investment story has moved beyond excessive and overly complicated stories.

Instead, investors are rewarding more direct approaches into the larger cannabis industry, according to the analyst. That approach may be paving the way for the new wave of investment for cannabis as part of the remainder for 2020.

Don’t forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated May 25, 2021 were elected as directors of the Company at Avicanna‘s annual general meeting of shareholders held on June 24, 2021 (the ” Meeting “). The detailed results of the vote for the election of directors held at the Meeting are set out below.

Keep reading... Show less

Quantum 1 Cannabis (CSE:QQ) announced its revenue for the third quarter of 2021 has increased by 672 percent and gross profit has increased by 463 percent compared with the same quarter in 2020. Quantum 1 Cannabis CEO Russ Rossi expounded on this exponential growth and what’s behind this remarkable leap. 

“We had an opportunity during our cannabis training to opt into some leases for cannabis retail. So we thought, let’s take a shot at this and see if we can use our experience with mobile location and supercharge. It paid off. It was a new game for everybody. It’s a lot of luck when opportunity meets preparation,” said Rossi. 

Quantum 1 Cannabis attributed the growth to high month-over-month sales coming from its flagship store in North Vancouver, improved demand for specialized “cottage-grown” sativa and indica products, continued training and hiring of best-of-breed staff and management to cater to consumer inquiries and expanded in-house technology for management of human resources, inventory and regulatory requirements. 

“Our plan is to have the maximum number of retail stores possible in British Columbia. We have 10 year leases on these stores, putting everything in on a solid pitch for the city council. I’m pretty confident that we’re going to have eight centers full blast in BC within six months,” explained Rossi. 

Quantum 1 Cannabis has signed a memorandum of understanding to acquire an approved municipal cannabis retail location in one of Vancouver’s most diverse neighborhoods at 41st Avenue and Cambie Street in Vancouver, British Columbia. The flagship location is expected to expand the company’s footprint in the Lower Mainland.

Watch the full interview with Quantum 1 Cannabis (CSE:QQ) CEO Russ Rossi above.

Keep reading... Show less

Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy.

Keep reading... Show less

Opening Marks Company’s 107th Retail Location Nationwide

Strategic Expansion Will Help Serve the State’s Rapidly Growing Cannabis Market

Keep reading... Show less

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less